Full CoverageTop news
All coverage
Your COVID vaccine booster might be a patch or a pill. Or it might come with your flu shot.
By Alexander Tin
Pfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues
By Kevin Breuninger
BioNTech nearing request for approval of longer-lasting version of COVID vaccine
By Ludwig Burger, Louise Heavens & Alistair Smout
BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says
By Noah Higgins-Dunn
Pfizer to seek authorization for Covid-19 vaccine for children ages 2 to 11 in September
By Naomi Thomas
How the Moderna, AstraZeneca, Pfizer and other Covid vaccines compare
By Annelies Gartner, Anne Gulland & Lizzie Roberts
Pfizer-BioNTech Vaccine is Highly Effective Against Variants, Studies Find (Published 2021)
By Emily Anthes
Pfizer seeks full FDA approval for COVID-19 vaccine beyond current emergency use
By William Mansell & Eric M. Strauss
Pfizer Seeks Full FDA Approval For COVID-19 Vaccine
By Emma Bowman
FDA preparing to authorize Pfizer Covid vaccine for 12- to 15-year-olds as early as next week
By Lauren Egan & Laura Strickler
Pfizer sees robust COVID-19 vaccine demand for years, $26 bln in 2021 sales
By Michael Erman & Manas Mishra
Pfizer and BioNTech begin the process of seeking full U.S. approval for their Covid vaccine
By Berkeley Lovelace, Berkeley Lovelace Jr. & Dawn Kopecki
Pfizer COVID vaccine for adolescents, boasting "100% efficacy," could be authorized by early next week
By Alexander Tin
Covid-19: F.D.A. to Authorize Pfizer Vaccine for Adolescents by Early Next Week (Published 2021)
By Apoorva Mandavilli, Kate Taylor & Will Wright
Pfizer Reaps Hundreds of Millions in Profits From Covid Vaccine (Published 2021)
By Rebecca Robbins & Peter S. Goodman